In today’s scenario, there are a lot of factors involved in the emergence of new infectious diseases or the re-emergence of ‘old’ ones, with Covid-19 being the latest example. And according to Baseimmune – a biotech startup, the current estimates indicate that about 70 per cent of the world’s population is at high risk for contracting fatal infectious diseases. This is where Baseimmune wants to make a difference.
Baseimmune raises funding
In a recent development, the London-based biotech startup that is combining big data and biological expertise to generate variant-proof vaccines has raised £685K (approx €803K) in a fresh round of funding.